Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 19.50 GBp
Change Today -0.50 / -2.50%
Volume 440.6K
TRX On Other Exchanges
As of 11:35 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

tissue regenix group plc (TRX) Snapshot

20.00 GBp
Previous Close
20.00 GBp
Day High
20.00 GBp
Day Low
19.50 GBp
52 Week High
06/17/14 - 29.00 GBp
52 Week Low
04/14/15 - 14.50 GBp
Market Cap
Average Volume 10 Days
-0.01 GBp
Shares Outstanding
Dividend Yield
Current Stock Chart for TISSUE REGENIX GROUP PLC (TRX)

Related News

No related news articles were found.

tissue regenix group plc (TRX) Related Businessweek News

No Related Businessweek News Found

tissue regenix group plc (TRX) Details

Tissue Regenix Group Plc, a medical devices company, develops and commercializes platform technologies in the field of tissue engineering and regenerative medicine in the United Kingdom and the United States. The company’s patented decellularisation (dCELL) technology process removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold, which can be used to repair diseased or worn-out body parts. The dCELL technology has applications in various clinical needs, such as wound care, heart valve replacement, and knee repair. It offers DermaPure, a decellularized human dermis product used to cover chronic wounds; and vascular patches for peripheral vascular reconstruction. The company also develops OrthoPure category products, which include meniscus products used to repair damages in the meniscus knee cartilage, as well as tendon products for anterior cruciate ligament repairs. In addition, it develops CardioPure HV, a human heart valve product. Tissue Regenix Group Plc was incorporated in 2006 and is based in York, the United Kingdom.

60 Employees
Last Reported Date: 05/11/15
Founded in 2006

tissue regenix group plc (TRX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 248.0K GBP
Chief Financial Officer, Company Secretary an...
Total Annual Compensation: 179.0K GBP
Compensation as of Fiscal Year 2015.

tissue regenix group plc (TRX) Key Developments

Tissue Regenix Group plc Reports Unaudited Consolidated Earnings Results for the Year Ended January 31, 2015

Tissue Regenix Group Plc reported unaudited consolidated earnings results for the year ended January 31, 2015. For the year, on the consolidated basis, the company reported operating income of £100,000 compared with £6,000 a year ago. Operating loss was £8,369,000 compared with £6,577,000 a year ago. Loss before taxation was £8,201,000 compared with £6,303,000 a year ago. Loss after tax attributable to equity holders of the parent was £7,581,000 or 1.19 pence basic and diluted per share compared with £5,593,000 or 0.88 pence basic and diluted per share a year ago. Net cash outflow from operations was £8,285,000 compared with £5,647,000 a year ago. Purchases of property, plant and equipment was £114,000 compared with £358,000 a year ago.

Tissue Regenix Group plc Secures Approval from CGS Medicare for Coverage of DermaPure Reimbursement

Tissue Regenix Group plc announced that it has secured approval from CGS Medicare for coverage of DermaPure reimbursement. CGS covers the states of Ohio and Kentucky and adds a further 1.9m Medicare beneficiaries who can now receive the outstanding clinical benefits of the product.

Tissue Regenix Group plc Announces TRX Wound Care Inc. Has Signed A New Regional Distribution Contract for DermaPure

Tissue Regenix Group Plc announced that TRX Wound Care Inc. has signed a new regional distribution contract for DermaPure® which is used in the treatment of chronic and acute wounds. There has been substantial commercial interest in Dermapure® since Tissue Regenix received notice of Local Coverage Determination (LCD) from Novitas, as announced on 5 March 2015 and effective from 9 April 2015. Novitas is a Medicare Administrative Contractor covering US states representing 8.9 million Medicare beneficiaries and is responsible for product coverage and reimbursement. Novitas is the largest of the eight reimbursement groups covering Medicare and Medicaid reimbursement claims in the US. This major new contract has been signed with an experienced surgical and wound care distribution network; the contract covers 2 of the 12 states that comprise the region covered by the Novitas reimbursement LCD notice and represents approximately 11% of the Medicare patients addressed by the notice. The contract is expected to be worth a minimum of $600,000 over the next 12 months and provides for additional areas to be covered by mutual agreement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TRX:LN 19.50 GBp -0.50

TRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation TRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,277.3x
Price/Book 11.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1,521.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TISSUE REGENIX GROUP PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at